Metabolic Profiling Reveals Diagnostic Biomarkers for Distinguishing Myocarditis From Acute Myocardial Infarction

IF 3.4 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Therapeutics Pub Date : 2025-04-16 DOI:10.1155/cdr/6292099

Yuting Chen, Xiu Liu, Chengying Hong, Shunyao Xu, Linling He, Zhenmi Liu, Huaisheng Chen, Yaowang Lin

{"title":"Metabolic Profiling Reveals Diagnostic Biomarkers for Distinguishing Myocarditis From Acute Myocardial Infarction","authors":"Yuting Chen, Xiu Liu, Chengying Hong, Shunyao Xu, Linling He, Zhenmi Liu, Huaisheng Chen, Yaowang Lin","doi":"10.1155/cdr/6292099","DOIUrl":null,"url":null,"abstract":"Background: Distinguishing between myocarditis (MC) and acute myocardial infarction (AMI) in the early stages is crucial due to their similar symptoms yet vastly different treatment protocols. This study seeks to utilize metabolomics techniques to differentiate between MC and AMI.Methods: Plasma samples from 15 patients with MC and 12 patients with AMI were collected. Metabolic profiles of plasma from the two groups of patients were obtained using ultra-high performance liquid chromatography–mass spectrometry (UHPLC-MS), identifying metabolites with significant differences.Results: We identified 30 significantly different metabolites in both diseases. In patients with MC, 17 metabolites were upregulated, including 5-hydroxy-L-tryptophan and LysoPC (18:2(9Z,12Z)), while 13 metabolites were downregulated, such as 11-cis-retinol, L-glutamate, and hydroxynicotinic acid. KEGG enrichment analysis revealed that the altered metabolites were enriched in tryptophan metabolism, linoleic acid metabolism, primary bile acid biosynthesis, nitrogen metabolism, and retinol metabolism. Biomarker analysis via receiver-operating characteristic curves highlighted 11-cis-retinol as the predominant biomarker, with an AUC value of 0.917.Conclusions: In conclusion, patients experiencing AMI and MC undergo significant metabolic reprogramming. Metabolites exhibiting abnormal expression in peripheral blood hold diagnostic value for distinguishing between AMI and MC in clinical settings. 11-cis-retinol proved to be the pivotal biomarker for AMI, potentially aiding in the development of a robust predictive model for distinguishing between MC and AMI in clinical settings.","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/6292099","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/cdr/6292099","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Distinguishing between myocarditis (MC) and acute myocardial infarction (AMI) in the early stages is crucial due to their similar symptoms yet vastly different treatment protocols. This study seeks to utilize metabolomics techniques to differentiate between MC and AMI.

Methods: Plasma samples from 15 patients with MC and 12 patients with AMI were collected. Metabolic profiles of plasma from the two groups of patients were obtained using ultra-high performance liquid chromatography–mass spectrometry (UHPLC-MS), identifying metabolites with significant differences.

Results: We identified 30 significantly different metabolites in both diseases. In patients with MC, 17 metabolites were upregulated, including 5-hydroxy-L-tryptophan and LysoPC (18:2(9Z,12Z)), while 13 metabolites were downregulated, such as 11-cis-retinol, L-glutamate, and hydroxynicotinic acid. KEGG enrichment analysis revealed that the altered metabolites were enriched in tryptophan metabolism, linoleic acid metabolism, primary bile acid biosynthesis, nitrogen metabolism, and retinol metabolism. Biomarker analysis via receiver-operating characteristic curves highlighted 11-cis-retinol as the predominant biomarker, with an AUC value of 0.917.

Conclusions: In conclusion, patients experiencing AMI and MC undergo significant metabolic reprogramming. Metabolites exhibiting abnormal expression in peripheral blood hold diagnostic value for distinguishing between AMI and MC in clinical settings. 11-cis-retinol proved to be the pivotal biomarker for AMI, potentially aiding in the development of a robust predictive model for distinguishing between MC and AMI in clinical settings.

Abstract Image

查看原文本刊更多论文

代谢谱揭示了区分心肌炎和急性心肌梗死的诊断性生物标志物

背景：早期区分心肌炎（MC）和急性心肌梗死（AMI）是至关重要的，因为它们的症状相似，但治疗方案却截然不同。本研究试图利用代谢组学技术来区分MC和AMI。方法：收集15例MC患者和12例AMI患者的血浆标本。采用超高效液相色谱-质谱法（UHPLC-MS）获取两组患者血浆代谢谱，鉴定代谢物差异显著。结果：我们在两种疾病中发现了30种显著不同的代谢物。在MC患者中，17种代谢物上调，包括5-羟基- l -色氨酸和LysoPC (18:2(9Z,12Z))， 13种代谢物下调，如11-顺式视黄醇、l -谷氨酸和羟基烟酸。KEGG富集分析显示，改变的代谢物富集于色氨酸代谢、亚油酸代谢、原胆汁酸生物合成、氮代谢和视黄醇代谢。生物标志物分析显示，11-顺式视黄醇为主要生物标志物，AUC值为0.917。结论：AMI和MC患者存在显著的代谢重编程。外周血代谢物异常表达对临床区分AMI和MC具有诊断价值。11-顺式视黄醇被证明是AMI的关键生物标志物，可能有助于建立一个强大的预测模型，以在临床环境中区分MC和AMI。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Therapeutics 医学-心血管系统

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged. Subject areas include (but are by no means limited to): Acute coronary syndrome Arrhythmias Atherosclerosis Basic cardiac electrophysiology Cardiac catheterization Cardiac remodeling Coagulation and thrombosis Diabetic cardiovascular disease Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF) Hyperlipidemia Hypertension Ischemic heart disease Vascular biology Ventricular assist devices Molecular cardio-biology Myocardial regeneration Lipoprotein metabolism Radial artery access Percutaneous coronary intervention Transcatheter aortic and mitral valve replacement.